ÂÜÀòÂÒÂ×

Morin Frick is a highly experienced scientist with a robust background in drug substance development and process optimization across multiple biotechnology companies. Currently serving as a Sr Scientist at Erasca, Inc. since April 2022, Morin previously held positions at Global Blood Therapeutics as a Scientist II and was instrumental in the development and commercial launch of Oxbryta® (voxelotor). Morin's earlier experience includes roles at Gilead Sciences, Array BioPharma, Cedarburg Hauser Pharmaceuticals, and a research assistant position at the University of Colorado Anschutz Medical Campus. Morin holds two Master’s degrees in Organic Chemistry from the University of Colorado and a Bachelor’s degree in Chemistry.